Hong Jae Chon, Seung Tae Kim, Sun Young Rha, Baek-Yeol Ryoo, Anthony B. El-Khoueiry, Do-Youn Oh, Jaspreet Singh Grewal, Jeongjun Kim, Hyunji (Karen) Ahn, Seung-Hee Ryu, Jinho Choi, Kiyean Nam. "A phase 1b/2, open-label study of selective Axl, Mer and CSF1R inhibitor adrixetinib (Q702) in combination with intravenous pembrolizumab in patients with selected advanced solid tumors: Results of a phase 1 study (QRNT-008).." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.2606